Roles of the hemagglutinin of influenza A virus in viral entry and development of antiviral therapeutics and vaccines

Protein and Cell

Volumn 1, Issue 4, 2010, Pages 342-354

  Jiang, Shibo ^a,b   Li, Runming ^b   Du, Lanying ^a   Liu, Shuwen ^b  

^a NEW YORK BLOOD CENTER   (United States)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

antiviral drugs; hemagglutinin; influenza A virus; vaccines; viral entry

Indexed keywords

ACETYLSTACHYFLIN; AMINOCAPROIC ACID; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; APROTININ; BENZOHYDROQUINONE DERIVATIVE; BERACTANT; BMY 27709; CALFACTANT; CL 385319; CL 62554; DIPALMITOYLPHOSPHATIDYLCHOLINE; ENFUVIRTIDE; HYDROQUINONE; HYDROQUINONE DERIVATIVE; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; LEUPEPTIN; LY 180299; NAFAMSTAT; PEPTIDE; PODOCARPIC ACID DERIVATIVE; PORACTANT; PROTEINASE INHIBITOR; RECOMBINANT VACCINE; STACHYFLIN; STACHYFLIN DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS VECTOR;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; BLEEDING; CARBOXY TERMINAL SEQUENCE; DRUG SYNTHESIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; INFLUENZA A; INFLUENZA VIRUS A; MEMBRANE FUSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN PROCESSING; PROTEIN TARGETING; RESPIRATORY DISTRESS SYNDROME; REVIEW; VACCINE PRODUCTION; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS PARTICLE; VIRUS RESISTANCE; VIRUS STRAIN; VIRUS TRANSMISSION;

INFLUENZA A VIRUS;

EID: 79953192523     PISSN: 1674800X     EISSN: 16748018     Source Type: Journal    
DOI: 10.1007/s13238-010-0054-6     Document Type: Review

References (111)

1. Amorij, J. P., Meulenaar, J., Hinrichs, W. L., Stegmann, T., Huckriede, A., Coenen, F., and Frijlink, H. W. (2007). Rational design of an influenza subunit vaccine powder with sugar glass technology: preventing conformational changes of haemagglutinin during freezing and freeze-drying. Vaccine 25, 6447-6457.
2. Barefoot, B. E., Athearn, K., Sample, C. J., and Ramsburg, E. A. (2009). Intramuscular immunization with a vesicular stomatitis virus recombinant expressing the influenza hemagglutinin provides post-exposure protection against lethal influenza challenge. Vaccine 28, 79-89.
3. Barouch, D. H., Pau, M. G., Custers, J. H., Koudstaal, W., Kostense, S., Havenga, M. J., Truitt, D. M., Sumida, S. M., Kishko, M. G., Arthur, J. C., et al (2004). Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol 172, 6290-6297.
4. Beppu, Y., Imamura, Y., Tashiro, M., Towatari, T., Ariga, H., and Kido, H. (1997). Human mucus protease inhibitor in airway fluids is a potential defensive compound against infection with influenza A and Sendai viruses. J Biochem 121, 309-316.
5. Biesova, Z., Miller, M. A., Schneerson, R., Shiloach, J., Green, K. Y., Robbins, J. B., and Keith, J. M. (2009). Preparation, characterization, and immunogenicity in mice of a recombinant influenza H5 hemagglutinin vaccine against the avian H5N1 A/Vietnam/1203/2004 influenza virus. Vaccine 27, 6234-6238.
6. Bizebard, T., Gigant, B., Rigolet, P., Rasmussen, B., Diat, O., Bösecke, P., Wharton, S. A., Skehel, J. J., and Knossow, M. (1995). Structure of influenza virus haemagglutinin complexed with a neutralizing antibody. Nature 376, 92-94.
7. Bodian, D. L., Yamasaki, R. B., Buswell, R. L., Stearns, J. F., White, J. M., and Kuntz, I. D. (1993). Inhibition of the fusion-inducing conformational change of influenza hemagglutinin by benzoquinones and hydroquinones. Biochemistry 32, 2967-2978.
8. Bright, R. A., Carter, D. M., Crevar, C. J., Toapanta, F. R., Steckbeck, J. D., Cole, K. S., Kumar, N. M., Pushko, P., Smith, G., Tumpey, T. M. et al (2008). Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS One 3, e1501.
9. Bullough, P. A., Hughson, F. M., Skehel, J. J., and Wiley, D. C. (1994). Structure of influenza haemagglutinin at the pH of membrane fusion. Nature 371, 37-43.
10. Carr, C. M., and Kim, P. S. (1993). A spring-loaded mechanism for the conformational change of influenza hemagglutinin. Cell 73, 823-832.
11. Chan, D. C., Fass, D., Berger, J. M., and Kim, P. S. (1997). Core structure of gp41 from the HIV envelope glycoprotein. Cell 89, 263-273.
12. Chan, D. C., Chutkowski, C. T., and Kim, P. S. (1998). Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc Natl Acad Sci U S A 95, 15613-15617.
13. Chen, Q., Kuang, H., Wang, H., Fang, F., Yang, Z., Zhang, Z., Zhang, X., and Chen, Z. (2009a). Comparing the ability of a series of viral protein-expressing plasmid DNAs to protect against H5N1 influenza virus. Virus Genes 38, 30-38.
14. Chen, Y., Qin, K., Wu, W. L., Li, G., Zhang, J., Du, H., Ng, M. H., Shih, J. W., Peiris, J. S., Guan, Y., et al. (2009b). Broad cross-protection against H5N1 avian influenza virus infection by means of monoclonal antibodies that map to conserved viral epitopes. J Infect Dis 199, 49-58.
15. Delano, W. L. 2005. The PyMOL molecular graphics system (http://www. pymol. org). DeLano Scientific LLC. 400, Oyster Point Blvd., Suite 213, South San Francisco, CA 94080-1918 USA.
16. DiNapoli, J. M., Nayak, B., Yang, L., Finneyfrock, B. W., Cook, A., Andersen, H., Torres-Velez, F., Murphy, B. R., Samal, S. K., Collins, P. L., et al. (2010). Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys. J Virol 84, 1489-1503.
17. Du, L., He, Y., Jiang, S., and Zheng, B. J. (2008). Development of subunit vaccines against severe acute respiratory syndrome. Drugs Today (Barc) 44, 63-73.
18. Du, L., Zhou, Y., and Jiang, S. (2010). Research and development of universal influenza vaccines. Microbes Infect 12, 280-286.
19. Durrer, P., Galli, C., Hoenke, S., Corti, C., Glück, R., Vorherr, T., and Brunner, J. (1996). H +-induced membrane insertion of influenza virus hemagglutinin involves the HA2 amino-terminal fusion peptide but not the coiled coil region. J Biol Chem 271, 13417-13421.
20. Dwyer, J. J., Wilson, K. L., Davison, D. K., Freel, S. A., Seedorff, J. E., Wring, S. A., Tvermoes, N. A., Matthews, T. J., Greenberg, M. L., and Delmedico, M. K. (2007). Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus. Proc Natl Acad Sci U S A 104, 12772-12777.
21. Ekiert, D. C., Bhabha, G., Elsliger, M. A., Friesen, R. H., Jongeneelen, M., Throsby, M., Goudsmit, J., and Wilson, I. A. (2009). Antibody recognition of a highly conserved influenza virus epitope. Science 324, 246-251.
22. Ellebedy, A. H., and Webby, R. J. (2009). Influenza vaccines. Vaccine 27, D65-D68.
23. Fleury, D., Wharton, S. A., Skehel, J. J., Knossow, M., and Bizebard, T. (1998). Antigen distortion allows influenza virus to escape neutralization. Nat Struct Biol 5, 119-123.
24. Gao, W., Soloff, A. C., Lu, X., Montecalvo, A., Nguyen, D. C., Matsuoka, Y., Robbins, P. D., Swayne, D. E., Donis, R. O., Katz, J. M., et al. (2006). Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization. J Virol 80, 1959-1964.
25. Garten, R. J., Davis, C. T., Russell, C. A., Shu, B., Lindstrom, S., Balish, A., Sessions, W. M., Xu, X., Skepner, E., Deyde, V., et al. (2009). Antigenic and genetic characteristics of swine-origin 2009 A (H1N1) influenza viruses circulating in humans. Science 325, 197-201.
26. Harrison, S. C. (2008). Viral membrane fusion. Nat Struct Mol Biol 15, 690-698.
27. Haynes, J. R. (2009). Influenza virus-like particle vaccines. Expert Rev Vaccines 8, 435-445.
28. Hoffman, L. R., Kuntz, I. D., and White, J. M. (1997). Structure-based identification of an inducer of the low-pH conformational change in the influenza virus hemagglutinin: irreversible inhibition of infectivity. J Virol 71, 8808-8820.
29. Hosoya, M., Matsuyama, S., Baba, M., Suzuki, H., and Shigeta, S. (1992). Effects of protease inhibitors on replication of various myxoviruses. Antimicrob Agents Chemother 36, 1432-1436.
30. Itoh, Y., Shinya, K., Kiso, M., Watanabe, T., Sakoda, Y., Hatta, M., Muramoto, Y., Tamura, D., Sakai-Tagawa, Y., Noda, T., et al. (2009). In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 460, 1021-1025.
31. Ji, H., Shu, W., Burling, T., Jiang, S., and Lu, M. (1999). Inhibition of HIV-1 infectivity by the gp41 core: role of a conserved hydrophobic cavity in membrane fusion. J Virol 73, 8578-8586.
32. Jiang, S., Lin, K., Strick, N., and Neurath, A. R. (1993). HIV-1 inhibition by a peptide. Nature 365, 113.
33. Jones, S., Evans, K., McElwaine-Johnn, H., Sharpe, M., Oxford, J., Lambkin-Williams, R., Mant, T., Nolan, A., Zambon, M., Ellis, J., et al. (2009). DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial. Vaccine 27, 2506-2512.
34. Kang, S. M., Yoo, D. G., Lipatov, A. S., Song, J. M., Davis, C. T., Quan, F. S., Chen, L. M., Donis, R. O., Compans, R. W., and Broliden, K. (2009). Induction of long-term protective immune responses by influenza H5N1 virus-like particles. PLoS ONE 4, e4667.
35. Kido, H., Yokogoshi, Y., Sakai, K., Tashiro, M., Kishino, Y., Fukutomi, A., and Katunuma, N. (1992). Isolation and characterization of a novel trypsin-like protease found in rat bronchiolar epithelial Clara cells. A possible activator of the viral fusion glycoprotein. J Biol Chem 267, 13573-13579.
36. Kido, H., Sakai, K., Kishino, Y., and Tashiro, M. (1993). Pulmonary surfactant is a potential endogenous inhibitor of proteolytic activation of Sendai virus and influenza A virus. FEBS Lett 322, 115-119.
37. Kido, H., Okumura, Y., Yamada, H., Le, T. Q., and Yano, M. (2007). Proteases essential for human influenza virus entry into cells and their inhibitors as potential therapeutic agents. Curr Pharm Des 13, 405-414.
38. Kielian, M., and Rey, F. A. (2006). Virus membrane-fusion proteins: more than one way to make a hairpin. Nat Rev Microbiol 4, 67-76.
39. Kilby, J. M., and Eron, J. J. (2003). Novel therapies based on mechanisms of HIV-1 cell entry. N Engl J Med 348, 2228-2238.
40. King, J. C. Jr, Cox, M. M., Reisinger, K., Hedrick, J., Graham, I., and Patriarca, P. (2009). Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirusexpressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months. Vaccine 27, 6589-6594.
41. Kreijtz, J. H., Suezer, Y., de Mutsert, G., van den Brand, J. M., van Amerongen, G., Schnierle, B. S., Kuiken, T., Fouchier, R. A., Löwer, J., Osterhaus, A. D., et al. (2009a). Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses. Vaccine 27, 6296-6299.
42. Kreijtz, J. H., Suezer, Y., de Mutsert, G., van den Brand, J. M., van Amerongen, G., Schnierle, B. S., Kuiken, T., Fouchier, R. A., Löwer, J., Osterhaus, A. D., et al. (2009b). Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques. J Infect Dis 199, 405-413.
43. Kubota-Koketsu, R., Mizuta, H., Oshita, M., Ideno, S., Yunoki, M., Kuhara, M., Yamamoto, N., Okuno, Y., and Ikuta, K. (2009). Broad neutralizing human monoclonal antibodies against influenza virus from vaccinated healthy donors. Biochem Biophys Res Commun 387, 180-185.
44. Lambert, D. M., Barney, S., Lambert, A. L., Guthrie, K., Medinas, R., Davis, D. E., Bucy, T., Erickson, J., Merutka, G., and Petteway, S. R. Jr. (1996). Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. Proc Natl Acad Sci U S A 93, 2186-2191.
45. Lasaro, M. O., and Ertl, H. C. (2009). New insights on adenovirus as vaccine vectors. Mol Ther 17, 1333-1339.
46. Le, T. Q., Kawachi, M., Yamada, H., Shiota, M., Okumura, Y., and Kido, H. (2006). Identification of trypsin I as a candidate for influenza A virus and Sendai virus envelope glycoprotein processing protease in rat brain. Biol Chem 387, 467-475.
47. Le, Q. M., Wertheim, H. F., Tran, N. D., van Doorn, H. R., Nguyen, T. H., and Horby, P., and the Vietnam H1N1 Investigation Team. (2010). A community cluster of oseltamivir-resistant cases of 2009 H1N1 influenza. N Engl J Med 362, 86-87.
48. Li, F. C., Choi, B. C., Sly, T., and Pak, A. W. (2008). Finding the real case-fatality rate of H5N1 avian influenza. J Epidemiol Community Health 62, 555-559.
49. Liu, S., Xiao, G., Chen, Y., He, Y., Niu, J., Escalante, C. R., Xiong, H., Farmar, J., Debnath, A. K., Tien, P., et al. (2004). Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors. Lancet 363, 938-947.
50. Liu, S., Wu, S., and Jiang, S. (2007). HIV entry inhibitors targeting gp41: from polypeptides to small-molecule compounds. Curr Pharm Des 13, 143-162.
51. Liu, J., Stevens, D. J., Haire, L. F., Walker, P. A., Coombs, P. J., Russell, R. J., Gamblin, S. J., and Skehel, J. J. (2009). Structures of receptor complexes formed by hemagglutinins from the Asian Influenza pandemic of 1957. Proc Natl Acad Sci U S A 106, 17175-17180.
52. Lu, M., Blacklow, S. C., and Kim, P. S. (1995). A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat Struct Biol 2, 1075-1082.
53. Luo, G., Colonno, R., and Krystal, M. (1996). Characterization of a hemagglutinin-specific inhibitor of influenza A virus. Virology 226, 66-76.
54. Luo, G., Torri, A., Harte, W. E., Danetz, S., Cianci, C., Tiley, L., Day, S., Mullaney, D., Yu, K. L., Ouellet, C., et al. (1997). Molecular mechanism underlying the action of a novel fusion inhibitor of influenza A virus. J Virol 71, 4062-4070.
55. Matrosovich, M. N., Matrosovich, T. Y., Gray, T., Roberts, N. A., and Klenk, H. D. (2004). Human and avian influenza viruses target different cell types in cultures of human airway epithelium. Proc Natl Acad Sci U S A 101, 4620-4624.
56. Miller, M. A., Viboud, C., Balinska, M., and Simonsen, L. (2009). The signature features of influenza pandemics-implications for policy. N Engl J Med 360, 2595-2598.
57. Minagawa, K., Kouzuki, S., and Kamigauchi, T. (2002). Stachyflin and acetylstachyflin, novel anti-influenza A virus substances, produced by Stachybotrys sp. RF-7260. II. Synthesis and preliminary structure-activity relationships of stachyflin derivatives. J Antibiot (Tokyo) 55, 165-171.
58. Mitchell, D. K., Ruben, F. L., and Gravenstein, S. (2005). Immunogenicity and safety of inactivated influenza virus vaccine in young children in 2003-2004. Pediatr Infect Dis J 24, 925-927.
59. Mitrasinovic, P. M. (2010). Advances in the structure-based design of the influenza A neuraminidase inhibitors. Curr Drug Targets 11, 315-326.
60. Murakami, M., Towatari, T., Ohuchi, M., Shiota, M., Akao, M., Okumura, Y., Parry, M. A., and Kido, H. (2001). Mini-plasmin found in the epithelial cells of bronchioles triggers infection by broad-spectrum influenza A viruses and Sendai virus. Eur J Biochem 268, 2847-2855.
61. Naeve, C. W., Hinshaw, V. S., and Webster, R. G. (1984). Mutations in the hemagglutinin receptor-binding site can change the biological properties of an influenza virus. J Virol 51, 567-569.
62. Ndifon, W., Wingreen, N. S., and Levin, S. A. (2009). Differential neutralization efficiency of hemagglutinin epitopes, antibody interference, and the design of influenza vaccines. Proc Natl Acad Sci U S A 106, 8701-8706.
63. Okumura, Y., Sato, H., Seiki, M., and Kido, H. (1997). Proteolytic activation of the precursor of membrane type 1 matrix metalloproteinase by human plasmin. A possible cell surface activator. FEBS Lett 402, 181-184.
64. Okumura, Y., Takahashi, E., Yano, M., Ohuchi, M., Daidoji, T., Nakaya, T., Bottcher, E., Garten, W., Klenk, H. D., and Kido, H. (2010). Novel type II transmembrane serine proteases, MSPL and TMPRSS13, proteolytically activate membrane fusion activity of hemagglutinin of highly pathogenic avian influenza viruses and induce their multicycle replication. J Virol, 10.
65. Pan, C. and Jiang, S. (2009). E14-F55 combination in M2 protein: a putative molecular determinant responsible for swine-origin influenza A virus transmission in humans. PLoS Curr Influenza RRN1044.
66. Pan, C., Cheung, B., Tan, S., Li, C., Li, L., Liu, S., and Jiang, S. (2010). Genomic signature and mutation trend analysis of pandemic (H1N1) 2009 influenza A virus. PLoS ONE 5, e9549.
67. Patel, A., Tran, K., Gray, M., Li, Y., Ao, Z., Yao, X., Kobasa, D., and Kobinger, G. P. (2009). Evaluation of conserved and variable influenza antigens for immunization against different isolates of H5N1 viruses. Vaccine 27, 3083-3089.
68. Perdue, M. L., García, M., Senne, D., and Fraire, M. (1997). Virulenceassociated sequence duplication at the hemagglutinin cleavage site of avian influenza viruses. Virus Res 49, 173-186.
69. Plotch, S. J., O'Hara, B., Morin, J., Palant, O., LaRocque, J., Bloom, J. D., Lang, S. A. J. Jr, DiGrandi, M. J., Bradley, M., Nilakantan, R., et al. (1999). IInhibition of influenza A virus replication by compounds interfering with the fusogenic function of the viral hemagglutinin. J Virol 73, 140-151.
70. Prabhu, N., Prabakaran, M., Ho, H. T., Velumani, S., Qiang, J., Goutama, M., and Kwang, J. (2009). Monoclonal antibodies against the fusion peptide of hemagglutinin protect mice from lethal influenza A virus H5N1 infection. J Virol 83, 2553-2562.
71. Quan, F. S., Steinhauer, D., Huang, C., Ross, T. M., Compans, R. W., and Kang, S. M. (2008). A bivalent influenza VLP vaccine confers complete inhibition of virus replication in lungs. Vaccine 26, 3352-3361.
72. Reed, M. L., Bridges, O. A., Seiler, P., Kim, J. K., Yen, H. L., Salomon, R., Govorkova, E. A., Webster, R. G., and Russell, C. J. (2010). The pH of activation of the hemagglutinin protein regulates H5N1 influenza virus pathogenicity and transmissibility in ducks. J Virol 84, 1527-1535.
73. Rogers, G. N., and Paulson, J. C. (1983). Receptor determinants of human and animal influenza virus isolates: differences in receptor specificity of the H3 hemagglutinin based on species of origin. Virology 127, 361-373.
74. Ruben, F. L. (2004). Inactivated influenza virus vaccines in children. Clin Infect Dis 38, 678-688.
75. Russell, R. J., Kerry, P. S., Stevens, D. J., Steinhauer, D. A., Martin, S. R., Gamblin, S. J., and Skehel, J. J. (2008). Structure of influenza hemagglutinin in complex with an inhibitor of membrane fusion. Proc Natl Acad Sci U S A 105, 17736-17741.
76. Safdar, A., and Cox, M. M. (2007). Baculovirus-expressed influenza vaccine. A novel technology for safe and expeditious vaccine production for human use. Expert Opin Investig Drugs 16, 927-934.
77. Sahini, L., Tempczyk-Russell, A., Agarwal, R., and Lau, A. T. Y. (2010). Large-scale sequence analysis of hemagglutinin of influenza A virus identifies conserved regions suitable for targeting an anti-viral response. PLoS ONE 5, e9268.
78. Sasaki, S., Jaimes, M. C., Holmes, T. H., Dekker, C. L., Mahmood, K., Kemble, G. W., Arvin, A. M., and Greenberg, H. B. (2007). Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines. J Virol 81, 215-228.
79. Schröder, E., Phillips, C., Garman, E., Harlos, K., and Crawford, C. (1993). X-ray crystallographic structure of a papain-leupeptin complex. FEBS Lett 315, 38-42.
80. Skehel, J. J., and Wiley, D. C. (2000). Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem 69, 531-569.
81. Smith, G. J. D., Vijaykrishna, D., Bahl, J., Lycett, S. J., Worobey, M., Pybus, O. G., Ma, S. K., Cheung, C. L., Raghwani, J., Bhatt, S., et al. (2009). Origins and evolutionary genomics of the 2009 swineorigin H1N1 influenza A epidemic. Nature 459, 1122-1125.
82. Smith, L. R., Wloch, M. K., Ye, M., Reyes, L. R., Boutsaboualoy, S., Dunne, C. E., Chaplin, J. A., Rusalov, D., Rolland, A. P., Fisher, C. L., et al. (2010). Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin. Vaccine 28, 2565-2572.
83. Staschke, K. A., Hatch, S. D., Tang, J. C., Hornback, W. J., Munroe, J. E., Colacino, J. M., and Muesing, M. A. (1998). Inhibition of influenza virus hemagglutinin-mediated membrane fusion by a compound related to podocarpic acid. Virology 248, 264-274.
84. Steinhauer, D. A. (1999). Role of hemagglutinin cleavage for the pathogenicity of influenza virus. Virology 258, 1-20.
85. Stephenson, I., Nicholson, K. G., Glück, R., Mischler, R., Newman, R. W., Palache, A. M., Verlander, N. Q., Warburton, F., Wood, J. M., and Zambon, M. C. (2003). Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial. Lancet 362, 1959-1966.
86. Stevens, J., Blixt, O., Tumpey, T. M., Taubenberger, J. K., Paulson, J. C., and Wilson, I. A. (2006). Structure and receptor specificity of the hemagglutinin from an H5N1 influenza virus. Science 312, 404-410.
87. Stieneke-Gröber, A., Vey, M., Angliker, H., Shaw, E., Thomas, G., Roberts, C., Klenk, H. D., and Garten, W. (1992). Influenza virus hemagglutinin with multibasic cleavage site is activated by furin, a subtilisin-like endoprotease. EMBO J 11, 2407-2414.
88. Sui, J., Hwang, W. C., Perez, S., Wei, G., Aird, D., Chen, L. M., Santelli, E., Stec, B., Cadwell, G., Ali, M., et al. (2009). Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 16, 265-273.
89. Tashiro, M., Klenk, H. D., and Rott, R. (1987). Inhibitory effect of a protease inhibitor, leupeptin, on the development of influenza pneumonia, mediated by concomitant bacteria. J Gen Virol 68, 2039-2041.
90. Taubenberger, J. K. (2006). The origin and virulence of the 1918 "Spanish" influenza virus. Proc Am Philos Soc 150, 86-112.
91. Tompkins, S. M., Lin, Y., Leser, G. P., Kramer, K. A., Haas, D. L., Howerth, E. W., Xu, J., Kennett, M. J., Durbin, R. K., Durbin, J. E., et al. (2007). Recombinant parainfluenza virus 5 (PIV5) expressing the influenza A virus hemagglutinin provides immunity in mice to influenza A virus challenge. Virology 362, 139-150.
92. Treanor, J. J., Campbell, J. D., Zangwill, K. M., Rowe, T., and Wolff, M. (2006). Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 354, 1343-1351.
93. Walensky, L. D., Kung, A. L., Escher, I., Malia, T. J., Barbuto, S., Wright, R. D., Wagner, G., Verdine, G. L., and Korsmeyer, S. J. (2004). Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science 305, 1466-1470.
94. Wang, H., Qi, Z., Guo, A., Mao, Q., Lu, H., An, X., Xia, C., Li, X., Debnath, A. K., Wu, S., et al. (2009). ADS-J1 inhibits HIV-1 entry by interacting with the gp41 pocket region and blocking the fusionactive gp41 core formation. Antimicrob Agents Chemother 53, 4987-4998.
95. Watts, G. (2009). A/H1N1 influenza virus: the basics. BMJ 339, b3046.
96. Wei, C. J., Xu, L., Kong, W. P., Shi, W., Canis, K., Stevens, J., Yang, Z. Y., Dell, A., Haslam, S. M., Wilson, I. A., et al. (2008). Comparative efficacy of neutralizing antibodies elicited by recombinant hemag-glutinin proteins from avian H5N1 influenza virus. J Virol 82, 6200-6208.
97. Weis, W., Brown, J. H., Cusack, S., Paulson, J. C., Skehel, J. J., and Wiley, D. C. (1988). Structure of the influenza virus haemagglutinin complexed with its receptor, sialic acid. Nature 333, 426-431.
98. Weissenhorn, W., Dessen, A., Harrison, S. C., Skehel, J. J., and Wiley, D. C. (1997). Atomic structure of the ectodomain from HIV-1 gp41. Nature 387, 426-430.
99. Weissenhorn, W., Carfí, A., Lee, K. H., Skehel, J. J., and Wiley, D. C. (1998). Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain. Mol Cell 2, 605-616.
100. Wild, C. T., Shugars, D. C., Greenwell, T. K., McDanal, C. B., and Matthews, T. J. (1994). Peptides corresponding to a predictive α-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci U S A 91, 9770-9774.
101. Wilson, I. A., Skehel, J. J., and Wiley, D. C. (1981). Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution. Nature 289, 366-373.
102. Xu, Y., Gao, S., Cole, D. K., Zhu, J., Su, N., Wang, H., Gao, G. F., and Rao, Z. (2004a). Basis for fusion inhibition by peptides: analysis of the heptad repeat regions of the fusion proteins from Nipah and Hendra viruses, newly emergent zoonotic paramyxoviruses. Biochem Biophys Res Commun 315, 664-670.
103. Xu, Y., Lou, Z., Liu, Y., Pang, H., Tien, P., Gao, G. F., and Rao, Z. (2004b). Crystal structure of severe acute respiratory syndrome coronavirus spike protein fusion core. J Biol Chem 279, 49414-49419.
104. Xu, R., McBride, R., Paulson, J. C., Basler, C. F., and Wilson, I. A. (2010). Structure, receptor binding, and antigenicity of influenza virus hemagglutinins from the 1957 H2N2 pandemic. J Virol 84, 1715-1721.
105. Yamashita, A., Kawashita, N., Kubota-Koketsu, R., Inoue, Y., Watanabe, Y., Ibrahim, M. S., Ideno, S., Yunoki, M., Okuno, Y., Takagi, T., et al. (2010). Highly conserved sequences for human neutralization epitope on hemagglutinin of influenza A viruses H3N2, H1N1 and H5N1: Implication for human monoclonal antibody recognition. Biochem Biophys Res Commun 393, 614-618.
106. Yoshimoto, J., Kakui, M., Iwasaki, H., Fujiwara, T., Sugimoto, H., and Hattori, N. (1999). Identification of a novel HA conformational change inhibitor of human influenza virus. Arch Virol 144, 865-878.
107. Yoshimoto, J., Kakui, M., Iwasaki, H., Sugimoto, H., Fujiwara, T., and Hattori, N. (2000a). Identification of amino acids of influenza virus HA responsible for resistance to a fusion inhibitor, Stachyflin. Microbiol Immunol 44, 677-685.
108. Yoshimoto, J., Yagi, S., Ono, J., Sugita, K., Hattori, N., Fujioka, T., Fujiwara, T., Sugimoto, H., and Hashimoto, N. (2000b). Development of anti-influenza drugs: II. Improvement of oral and intranasal absorption and the anti-influenza activity of stachyflin derivatives. J Pharm Pharmacol 52, 1247-1255.
109. Zhang, H., Zhao, Q., Bhattacharya, S., Waheed, A. A., Tong, X., Hong, A., Heck, S., Curreli, F., Goger, M., Cowburn, D., et al. (2008). A cell-penetrating helical peptide as a potential HIV-1 inhibitor. J Mol Biol 378, 565-580.
110. Zhirnov, O. P., Ovcharenko, A. V., and Bukrinskaya, A. G. (1984). Suppression of influenza virus replication in infected mice by protease inhibitors. J Gen Virol 65, 191-196.
111. Zhu, J., Xiao, G., Xu, Y., Yuan, F., Zheng, C., Liu, Y., Yan, H., Cole, D. K., Bell, J. I., Rao, Z., et al. (2004). Following the rule: formation of the 6-helix bundle of the fusion core from severe acute respiratory syndrome coronavirus spike protein and identification of potent peptide inhibitors. Biochem Biophys Res Commun 319, 283-288.